计算溶液所需的质量、体积或浓度。
提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
2-8°C储存,避光,充氩。低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Osimertinib-d 6 is a deuterium labeled osimertinib. Osimertinib is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
In Vitro
Osimertinib (AZD9291) (0-10 μM; 72 hours) dramatically inhibits cell proliferation with IC 50 s of 41, 26, 41, and 31 nM, respectively. Osimertinib (0-10 μM; 72 hours) inhibits cell proliferation (Ba/F3 cells harboring a T790M mutation, exon 19del+T790M, or L858R+T790M) with IC 50 s of 6, 7, and 74 nM, respectively. Osimertinib (0-10 μM; 72 hours) inhibits Ba/F3 cells harboring EGFR exon 20 insertion mutations (IC 50 ranging from 16-701 nM for A763_Y764insFQEA (FQEA), Y764_V765insHH (HH), A767_V769dupASV (ASV), and D770_N771insNPG (NPG) cells). Osimertinib shows high levels of phenotype potency in both sensitizing-mutant (mean IC 50 of 8 nM in PC-9) and T790M (mean IC 50 of 11 and 40 nM in H1975 and PC-9VanR respectively) EGFR cell lines. Osimertinib has much less activity towards wild-type EGFR (mean IC 50 of 650 and 461 nM in Calu3 and H2073 respectively). Osimertinib (0.1 μM; 48 hours) induces apoptosis in Ba/F3 cells (apoptosis rate of 40.9% and 90% in EGFR exon 19del+T790M, EGFR L858R+T790M respectively). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: PC-9, H3255, PC-9ER, and H1975 cells Concentration: 0.0001, 0.001, 0.01, 0.1, 1, 10 μM Incubation Time: 72 hours Result: Dramatically inhibited cell proliferation (IC 50 =41,26, 41, 31 nM, respectively) Cell Proliferation AssayCell Line: Ba/F3 cells (harboring a T790M mutation, exon 19del+T790M, or L858R+T790M) Concentration: 0.0001, 0.001, 0.01, 0.1, 1, 10 μM Incubation Time: 72 hours Result: Inhibited cell proliferation (IC 50 = 6, 7, 74 nM, respectively) Apoptosis AnalysisCell Line: Ba/F3 cells (harboring EGFR exon 20 insertion mutations) Concentration: 0.0001, 0.001, 0.01, 0.1, 1, 10 μM Incubation Time: 72 hours Result: Inhibited cell proliferation (IC 50 = 16, 701, 230, 38 nM, respectively) Apoptosis AnalysisCell Line: Ba/F3 cells(harboring EGFR exon 19del+T790M or EGFR L858R+T790M) Concentration: 0.1 μM Incubation Time: 48 hours Result: Inducted apoptosis with the rate of 40.9% and 90% in EGFR T790M positive mutations cells respectively.
In Vivo
Osimertinib (0.1-25 mg/kg; p.o.; daily for 14 day) induces significant dose-dependent regression in both PC-9 (ex19del) and H1975 (L858R/T790M) tumor xenograft models . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: PC-9 (ex19del) and H1975 (L858R/T790M) tumor xenograft models Dosage: 0.1-10 mg/kg (PC-9 xenograft models); 0.5- 25 mg/kg (H1975 xenograft models) Administration: p.o.; daily for 14 day Result: Induced significant dose-dependent regression in both PC-9 (ex19del) and H1975 (L858R/T790M) tumor xenograft models.
Form:Solid
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 苯类化合物 |
| 类(Class) | 苯及其取代衍生物 |
| 亚类(Subclass) | 苯胺类 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 2'-氨基苯胺 |
| 其他上位类(Alternative Parents) | N-烷基吲哚 氨基苯醚 吲哚 甲氧基苯胺 茴香醚 二烷基芳胺 苯氧基化合物 甲氧基苯 N-芳基酰胺 烷基芳基醚 氨基嘧啶及其衍生物 N-甲基吡咯 杂芳族化合物 丙烯酸及其衍生物 仲羧酸酰胺 氨基酸及其衍生物 三烷基胺 氮杂环化合物 碳氢化合物衍生物 羰基化合物 有机氧化物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 2'-氨基苯胺 - 丙烯酸或衍生物 - 芳基醚 - 氨基酸 - 氨基酸或其衍生物 - 氨基苯醚 - 氨基吡啶 - 苯胺或取代苯胺 - 茴香醚 - 芳香族杂多环化合物 - 氮杂环 - 羰基 - 羧酰胺基 - 羧酸衍生物 - 二烷基芳基胺 - 乙醚 - 杂芳香族化合物 - 烃衍生物 - 吲哚 - 吲哚或其衍生物 - 甲氧基苯胺 - 甲氧基苯 - N-烷基吲哚 - N-芳基酰胺 - N-甲基吡咯 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机杂环化合物 - 有机氮化合物 - 有机氧化合物 - 苯酚醚 - 苯氧基化合物 - 嘧啶 - 吡咯 - 醛基 - 取代吡咯 - 三元脂肪胺 - 三级脂肪族/芳香族胺 - 三芳基胺 |
| 描述(Description) | 该化合物属于有机化合物类别中的2'-氨基苯胺类。这类化合物含有苯环2位带氨基的苯胺基团。 |
| 外部描述符(External Descriptors) | 暂无 |